Scholarlink

<p>Obesity is a known risk factor for Pancreatic ductal adenocarcinoma (PDAC). Fatty acid binding protein 4 (FABP4) is higher in plasma of obese patients, and linked to the progression of obesity-related cancers. To provide insights into the role of FABP4 in PDAC progression and determine the potential of FABP4 inhibitor for PDAC treatment, we elucidated the anticancer mechanism of FABP4 inhibition using FABP4 null mice and FABP4 inhibitor (HTS01037). In vitro, HTS010137 suppressed FABP4-induced cell viability in mouse (KPC cells) and human PDAC cell lines. FABP4 promoted invasive potency, epithelial–mesenchymal transition (EMT), and cancer stemness markers that were associated with up-regulation of transcription factor ZEB1. In vivo, both FABP4 knockout and inhibition with HTS01037 suppressed syngeneic KPC subcutaneous tumor growth with reduction of EMT and stemness and down-regulation of ZEB1. Human xenograft growth was also inhibited by HTS01037 treatment. In an orthotopic model, HTS01037 significantly suppressed tumor growth which improved distant metastases and survivals in mice. In liver metastasis mouse model, HTS01037 attenuated development and growth of liver metastases. Moreover, HTS01037 enhanced the efficacy of gemcitabine to PDAC. These findings indicate a promising translational value of FABP4 inhibitor as a critical therapeutic option in PDAC patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inhibition of fatty acid binding protein suppresses pancreatic cancer progression and metastasis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月18日

查看全文
  • Shuhei Shinoda,
  • Naohiko Nakamura,
  • Kazuho Inoko,
  • Mizuho Sato-Dahlman,
  • Steven Carmella,
  • Stephen Hecht,
  • David A Bernlohr,
  • Sayeed Ikramuddin,
  • Masato Yamamoto

摘要

Obesity is a known risk factor for Pancreatic ductal adenocarcinoma (PDAC). Fatty acid binding protein 4 (FABP4) is higher in plasma of obese patients, and linked to the progression of obesity-related cancers. To provide insights into the role of FABP4 in PDAC progression and determine the potential of FABP4 inhibitor for PDAC treatment, we elucidated the anticancer mechanism of FABP4 inhibition using FABP4 null mice and FABP4 inhibitor (HTS01037). In vitro, HTS010137 suppressed FABP4-induced cell viability in mouse (KPC cells) and human PDAC cell lines. FABP4 promoted invasive potency, epithelial–mesenchymal transition (EMT), and cancer stemness markers that were associated with up-regulation of transcription factor ZEB1. In vivo, both FABP4 knockout and inhibition with HTS01037 suppressed syngeneic KPC subcutaneous tumor growth with reduction of EMT and stemness and down-regulation of ZEB1. Human xenograft growth was also inhibited by HTS01037 treatment. In an orthotopic model, HTS01037 significantly suppressed tumor growth which improved distant metastases and survivals in mice. In liver metastasis mouse model, HTS01037 attenuated development and growth of liver metastases. Moreover, HTS01037 enhanced the efficacy of gemcitabine to PDAC. These findings indicate a promising translational value of FABP4 inhibitor as a critical therapeutic option in PDAC patients.